Biomedical Engineering Reference
In-Depth Information
30. Smith, S.Y., Recker, R.R., Hannan, M., Muller, R., Bauss, F.: Intermittent intravenous
administration of the bisphosphonate ibandronate prevents bone loss and maintains bone
strength and quality in ovariectomized cynomolgus monkeys. Bone 32, 45-55 (2003)
31. Bone, H.G., Downs Jr., R.W., Tucci, J.R., Harris, S.T., Weinstein, R.S., Licata, A.A.,
McClung, M.R., Kimmel, D.B., Gertz, B.J., Hale, E., Polvino, W.J.: Dose-response
relationships for alendronate treatment in osteoporotic elderly women. Alendronate elderly
osteoporosis study centers. J. Clin. Endocrinol. Metab. 82, 265-274 (1997)
32. Bonnick, S., Saag, K.G., Kiel, D.P., McClung, M., Hochberg, M., Burnett, S.M., Sebba, A.,
Kagan, R., Chen, E., Thompson, D.E., de Papp, A.E.: Comparison of weekly treatment of
postmenopausal osteoporosis with alendronate versus risedronate over two years. J. Clin.
Endocrinol. Metab. 91, 2631-2637 (2006)
33. Rosen, C.J., Hochberg, M.C., Bonnick, S.L., McClung, M., Miller, P., Broy, S., Kagan, R.,
Chen, E., Petruschke, R.A., Thompson, D.E., de Papp, A.E.: Treatment with once-weekly
alendronate 70 mg compared with once-weekly risedronate 35 mg in women with
postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20,
141-151 (2005)
34. Reid, I.R., Miller, P., Lyles, K., Fraser, W., Brown, J.P., Saidi, Y., Mesenbrink, P., Su, G.,
Pak, J., Zelenakas, K., Luchi, M., Richardson, P., Hosking, D.: Comparison of a single
infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898-
908 (2005)
35. Borah, B., Ritman, E.L., Dufresne, T.E., Jorgensen, S.M., Liu, S., Sacha, J., Phipps, R.J.,
Turner, R.T.: The effect of risedronate on bone mineralization as measured by micro-
computed tomography with synchrotron radiation: correlation to histomorphometric indices
of turnover. Bone 37, 1-9 (2005)
36. Chavassieux, P.M., Arlot, M.E., Reda, C., Wei, L., Yates, A.J., Meunier, P.J.:
Histomorphometric assessment of the long-term effects of alendronate on bone quality
and remodeling in patients with osteoporosis. J. Clin. Invest. 100, 1475-1480 (1997)
37. Recker, R.R., Weinstein, R.S., Chesnut 3rd, C.H., Schimmer, R.C., Mahoney, P., Hughes, C.,
Bonvoisin, B., Meunier, P.J.: Histomorphometric evaluation of daily and intermittent oral
ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
Osteoporos. Int. 15, 231-237 (2004)
38. Recker, R.R., Delmas, P.D., Halse, J., Reid, I.R., Boonen, S., Garcia-Hernandez, P.A.,
Supronik, J., Lewiecki, E.M., Ochoa, L., Miller, P., Hu, H., Mesenbrink, P., Hartl, F.,
Gasser, J., Eriksen, E.F.: Effects of intravenous zoledronic acid once yearly on bone
remodeling and bone structure. J. Bone Miner. Res. 23, 6-16 (2008)
39. Allen, M.R., Kubek, D.J., Burr, D.B.: Cancer treatment dosing regimens of zoledronic acid
result in near-complete suppression of mandible intracortical bone remodeling in beagle
dogs. J. Bone Miner. Res. 25, 98-105 (2010)
40. Allen, M.R., Burr, D.B.: Mandible matrix necrosis in beagle dogs after 3 years of daily oral
bisphosphonate treatment. J. Oral. Maxillofac. Surg. 66, 987-994 (2008)
41. Allen, M.R., Follet, H., Khurana, M., Sato, M., Burr, D.B.: Antiremodeling agents influence
osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif. Tissue
Int. 79, 255-261 (2006)
42. Allen, M.R., Reinwald, S., Burr, D.B.: Alendronate reduces bone toughness of ribs without
significantly increasing microdamage accumulation in dogs following 3 years of daily
treatment. Calcif. Tissue Int. 82, 354-360 (2008)
43. Silverman, S.L., Watts, N.B., Delmas, P.D., Lange, J.L., Lindsay, R.: Effectiveness of
bisphosphonates
on
nonvertebral
and
hip
fractures
in
the
first
year
of
therapy:
the
risedronate and alendronate (REAL) cohort study. Osteoporos. Int. 18, 25-34 (2007)
44. Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-
Portales, J., Downs Jr., R.W., Dequeker, J., Favus, M.: Effect of oral alendronate on bone
mineral density and the incidence of fractures in postmenopausal osteoporosis. The
alendronate phase III osteoporosis treatment study group. N. Engl. J. Med. 333, 1437-1443
(1995)
Search WWH ::
Custom Search